Prescription Dermatology Therapeutics Market – Snapshot

The global prescription dermatology therapeutics market is growing at a rapid pace due to high prevalence and increase in incidence rate of chronic and infectious dermatological disorders, and new product development and commercialization across the globe. In terms of revenue, the global market was valued at US$ 27,580.0 Mn in 2017 and is projected to reach US$ 61,296.1 Mn by 2026, expanding at a CAGR of 9.5% from 2018 to 2026. The global prescription dermatology therapeutics market is also driven by rise in adoption of biologics for the treatment of moderate to severe dermatological disorders, especially psoriasis, and large patient population with unmet medical needs across the globe.

prescription dermatology therapeutics market

Skin is the largest organ of the body and the first point of contact for microbes and toxins. It contains a rich habitat of microbes which results in various dysfunctions. This is where dermatology steps in. Dermatological disorders differ across the globe based on geographic location, climatic conditions, socioeconomic status, lifestyles, age, gender, heredity, and personal habits. The importance of skin has increased in the past few years. Large number of people is willing to treat various dermatological diseases due to awareness. Increase in the number of indications treated with topical drugs is projected to propel the global prescription dermatology drugs market.

The global prescription dermatology therapeutics market is driven by intensive research to provide treatments and/or relieve the symptoms of chronic dermatological disorders. There is large patient population suffering from dermatology disorders with unmet medical needs and the number is increasing across the globe. Leading pharmaceutical companies are striving to address these unmet medical needs through new product development. Large number of both small molecules and biologic products are under different phases of clinical trials for the treatment of dermatology disorders. Companies have made significant investments in clinical R&D and have also established strategic partnerships and collaborations to accelerate new product development. For instance, as of March 31, 2018, Aurobindo Pharma had around 38 products under development in dermatology therapeutics in topical forms. Additionally, the company has around 24 products in the portfolio that need clinical trials. High prevalence and rise in incidence rates of chronic dermatological disorders with significant unmet medical needs are projected to propel the global prescription dermatology therapeutics market during the forecast period.

The global prescription dermatology therapeutics market has been segmented based on product, distribution channel, and region. In terms of product, the global market has been classified into acne & rosacea drugs, psoriasis drugs, dermatitis & seborrhea drugs, fungal infection drugs, skin cancer drugs, and others. The psoriasis drugs segment dominated the global market in 2017. The segment is projected to gain market share by 2026. Large patient population with psoriasis, long term management of moderate to severe plaque psoriasis, and high cost of biologic drugs have contributed to the segment’s high market share in 2017. An estimated 125 million people across the globe are affected with psoriasis.

Based on distribution channel, the global prescription dermatology therapeutics market has been divided into hospital pharmacies, retail pharmacies, and mail order pharmacies. The hospital pharmacies segment dominated the global market in 2017 and is projected to gain market share by 2026. Long-term management of chronic dermatological disorders, increase in rate of hospitalization, and availability of high cost biologic drugs are attributed to the segment’s large share of the market in 2017. The hospital pharmacies segment is anticipated to witness strong growth during the forecast period.

In terms of region, the global prescription dermatology therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account for significant share of 45% of the global market by 2026. High prevalence of chronic skin disorders, increase in adoption of biologic drugs for the treatment of moderate to severe plaque psoriasis, and anticipated new product approvals are likely to fuel the growth of the prescription dermatology therapeutics market in North America. The market in Asia Pacific is projected to expand at the highest CAGR during the forecast period. Increase in awareness about various skin disorders, rapidly changing health care infrastructure, rise in access to skin care treatments in the developing countries such as China and India, well-established pharmaceutical market in Japan, and surge in adoption of biologic drugs in Australia and New Zealand are anticipated to fuel the growth of the prescription dermatology therapeutics market in Asia Pacific during the forecast period.

Majority of biopharmaceutical companies have made significant investments in the clinical research and development of dermatology disorders treatment products. Mergers and acquisitions among leading players was the key trend in the global market in the past few years. Key players operating in the global prescription dermatology therapeutics market include AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., LEO Pharma A/S, Eli Lilly and Company, Bausch Health Companies, Inc., Sun Pharmaceuticals Ltd., Aclaris Therapeutics, Inc., and Aurobindo Pharma Ltd.

Prescription Dermatology Therapeutics Market to Gain Momentum Attributable to Increasing Number of Dermatological Issues

Skin is the biggest organ of the body and the main resource for microorganisms and poisons. It contains a rich territory of microorganisms which brings about different dysfunctions. This is the place where dermatology steps in. Dermatological issues contrast across the globe dependent on geographic area, climatic conditions, financial status, and ways of life, age, sex, heredity, and individual propensities. The significance of skin has expanded in the previous few years. Enormous number of individuals will treat different dermatological illnesses because of mindfulness. Expansion in the quantity of signs treated with skin drugs is projected to drive the worldwide prescription dermatology drugs market.

The worldwide prescription dermatology therapeutics market is driven by escalated examination to give therapies and additionally ease the indications of constant dermatological problems. There is huge patient populace experiencing dermatology issues with neglected clinical requirements and the number is expanding across the globe. Driving drug organizations are endeavoring to address these neglected clinical necessities through new item improvement. Huge number of both little atoms and biologic items are under various periods of clinical preliminaries for the treatment of dermatology problems. Organizations have made critical interests in clinical R&D and have likewise settled key associations and coordinated efforts to speed up new item advancement.

The worldwide prescription dermatology therapeutics market is required to enroll a strong development soon, because of developing occurrences of irresistible dermatological problems and persistent sicknesses. The market is additionally expected to go through a few unique moves because of new item advancements not too far off and expanded development of the medical care area in arising countries. Significant parts in the worldwide prescription dermatology therapeutics market are putting resources into R&D to catch more freedoms made by progresses like 3D printing, huge information, and difficulties like expiry of a few licenses.

Prescription Dermatology Therapeutics Market - Overview

This report by Transparency Market Research analyzes the global prescription dermatology therapeutics market for the period between 2018 and 2026. An in-depth and unbiased market assessment has been made which offers readers an in-depth and accurate analysis. Market projections have been offered in terms of value (US$ Mn). Stakeholders of this report include companies and intermediaries engaged in research & development, manufacture, and marketing of products prescribed in the treatment of various skin conditions.

The global prescription dermatology therapeutics market has been studied for the forecast period from 2018 to 2026. For research, 2017 has been considered as the base year and 2016 as the historical year. The global prescription dermatology therapeutics market report comprises an elaborate executive summary that provides overall information about various segments of the market. The report provides a detailed competitive landscape, by major players operating in this market along with their shares (value %) of the global prescription dermatology therapeutics market for 2017. The report also provides detailed company profiles of emerging market players operating in the global prescription dermatology therapeutics market.

The market overview section comprises impact factors such as key market dynamics including drivers, restraints, and opportunities, affecting the global prescription dermatology therapeutics market. These factors are likely to aid stakeholders establish a strong foothold in the global prescription dermatology therapeutics market. Furthermore, the market overview section comprises key industry events, pipeline analysis, key mergers & acquisitions across the dermatology industry, epidemiology analysis of the skin diseases, product portfolio overview of leading players, and market attractiveness analysis in the global prescription dermatology therapeutics market. The market attractiveness analysis provides a graphical view comparing the expansion and market dynamics in various segments and countries to identify the most attractive market.

Scope

The global prescription dermatology therapeutics market has been segmented based product type, distribution channel, and region. In terms of product type, the global market has been classified into acne & rosacea drugs, psoriasis drugs, dermatitis & seborrhea drugs, fungal infection drugs, skin cancer, and others. In terms of distribution channel, the global prescription dermatology therapeutics market has been categorized into hospital pharmacies, retail pharmacies, and mail order pharmacies.

In terms of region, the global prescription dermatology therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, quantitative analysis for major countries comprising the U.S., Canada, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, and Australia & New Zealand has also been provided in the report. A detailed qualitative analysis of factors responsible for driving and restraining the global market in various regions has been provided in this section.

The report provides a detailed outline/blueprint of the global prescription dermatology therapeutics market which is expected to assist new companies establish their presence and companies to expand their share in the market. The report concludes with the company profiles section, which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies, and recent developments of key players.

Competitive landscape

Major players operating in the global prescription dermatology therapeutics market include AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., LEO Pharma A/S, Eli Lilly and Company, Bausch Health Companies, Inc., Sun Pharmaceuticals Ltd., Aclaris Therapeutics, Inc., and Aurobindo Pharma Ltd.

The global prescription dermatology therapeutics market has been segmented into:

Product Type

  • Acne & Rosacea Drugs
  • Psoriasis Drugs
  • Dermatitis & Seborrhea Drugs
  • Fungal Infection Drugs
  • Skin Cancer Drugs
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Prescription Dermatology Therapeutics Market

4. Market Overview
     4.1. Introduction
            4.1.1. Product Type Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, 2016–2026 
            4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook
     5.1.Pipeline Analysis
     5.2.Key Mergers & Acquisitions 
     5.3.Disease Prevalence & Incidence Rate globally with key countries

6. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Product Type 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Market Value Forecast, by Product Type, 2016–2026
            6.3.1. Acne & Rosacea Drugs
            6.3.2. Psoriasis Drugs
            6.3.3. Dermatitis & Seborrhea Drugs
            6.3.4. Fungal Infection Drugs
            6.3.5. Skin Cancer Drugs
            6.3.6. Others
     6.4. Market Attractiveness, by Product Type 

7. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Distribution Channel 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Value Forecast, by Distribution Channel, 2016–2026
            7.3.1. Hospital Pharmacies
            7.3.2. Retail Pharmacies
            7.3.3. Mail Order Pharmacies
     7.4. Market Attractiveness, by Distribution Channel 

8. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Region
     8.1. Key Findings
     8.2. Market Value Forecast, by Region
            8.2.1. North America 
            8.2.2. Europe 
            8.2.3. Asia Pacific 
            8.2.4. Latin America 
            8.2.5. Middle East & Africa 
     8.3. Market Attractiveness, by Country/Region

9. North America Prescription Dermatology Therapeutics Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
     9.2. Market Value Forecast, by Product Type, 2016–2026
            9.2.1. Acne & Rosacea Drugs
            9.2.2. Psoriasis Drugs
            9.2.3. Dermatitis & Seborrhea Drugs
            9.2.4. Fungal Infection Drugs
            9.2.5. Skin Cancer Drugs
            9.2.6. Others
     9.3. Market Value Forecast, by Distribution Channel, 2016–2026
            9.3.1. Hospital Pharmacies
            9.3.2. Retail Pharmacies
            9.3.3. Mail Order Pharmacies
     9.4. Market Value Forecast, by Country, 2016–2026
            9.4.1. U.S.
            9.4.2. Canada
     9.5. Market Attractiveness Analysis 
            9.5.1. By Product Type 
            9.5.2. By Distribution Channel 
            9.5.3. By Country

10. Europe Prescription Dermatology Therapeutics Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. Market Value Forecast, by Product Type, 2016–2026
            10.2.1. Acne & Rosacea Drugs
            10.2.2. Psoriasis Drugs
            10.2.3. Dermatitis & Seborrhea Drugs
            10.2.4. Fungal Infection Drugs
            10.2.5. Skin Cancer Drugs
            10.2.6. Others
     10.3. Market Value Forecast, by Distribution Channel, 2016–2026
            10.3.1. Hospital Pharmacies
            10.3.2. Retail Pharmacies
            10.3.3. Mail Order Pharmacies
     10.4. Market Value Forecast, by Country/Sub-region, 2016–2026
            10.4.1. Germany
            10.4.2. U.K.
            10.4.3. France
            10.4.4. Spain
            10.4.5. Italy
            10.4.6. Rest of Europe
     10.5. Market Attractiveness Analysis 
            10.5.1. By Product Type 
            10.5.2. By Distribution Channel 
            10.5.3. By Country/Sub-region

11. Asia Pacific Prescription Dermatology Therapeutics Market Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
     11.2.Market Value Forecast, by Product Type, 2016–2026
            11.2.1. Acne & Rosacea Drugs
            11.2.2. Psoriasis Drugs
            11.2.3. Dermatitis & Seborrhea Drugs
            11.2.4. Fungal Infection Drugs
            11.2.5. Skin Cancer Drugs
            11.2.6. Others
     11.3.Market Value Forecast, by Distribution Channel, 2016–2026
            11.3.1. Hospital Pharmacies
            11.3.2. Retail Pharmacies
            11.3.3. Mail Order Pharmacies
     11.4.Market Value Forecast, by Country/Sub-region, 2016–2026
            11.4.1. China
            11.4.2. Japan
            11.4.3. India
            11.4.4. Australia & New Zealand
            11.4.5. Rest of Asia Pacific
     11.5.Market Attractiveness Analysis 
            11.5.1. By Product Type 
            11.5.2. By Distribution Channel 
            11.5.3. By Country/Sub-region

12. Latin America Prescription Dermatology Therapeutics Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
     12.2.Market Value Forecast, by Product Type, 2016–2026
            12.2.1. Acne & Rosacea Drugs
            12.2.2. Psoriasis Drugs
            12.2.3. Dermatitis & Seborrhea Drugs
            12.2.4. Fungal Infection Drugs
            12.2.5. Skin Cancer Drugs
            12.2.6. Others
     12.3.Market Value Forecast, by Distribution Channel, 2016–2026
            12.3.1. Hospital Pharmacies
            12.3.2. Retail Pharmacies
            12.3.3. Mail Order Pharmacies
     12.4.Market Value Forecast, by Country/Sub-region, 2016–2026
            12.4.1. Brazil
            12.4.2. Mexico
            12.4.3. Rest of Latin America
     12.5.Market Attractiveness Analysis 
            12.5.1. By Product Type 
            12.5.2. By Distribution Channel 
            12.5.3. By Country/Sub-region

13. Middle East & Africa Prescription Dermatology Therapeutics Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
     13.2.Market Value Forecast, by Product Type, 2016–2026
            13.2.1. Acne & Rosacea Drugs
            13.2.2. Psoriasis Drugs
            13.2.3. Dermatitis & Seborrhea Drugs
            13.2.4. Fungal Infection Drugs
            13.2.5. Skin Cancer Drugs
            13.2.6. Others
    13.3 Market Value Forecast, by Distribution Channel, 2016–2026
            13.3.1. Hospital Pharmacies
            13.3.2. Retail Pharmacies
            13.3.3. Mail Order Pharmacies
    13.4.Market Value Forecast, by Country/Sub-region, 2016–2026
            13.4.1. GCC Countries
            13.4.2. South Africa
            13.4.3. Rest of Middle East & Africa
            13.5.Market Attractiveness Analysis 
            13.5.1. By Product Type 
            13.5.2. By Distribution Channel 
            13.5.3. By Country/Sub-region

14. Competition Landscape
     14.1.Market Player - Competition Matrix (By Tier and Size of companies)
     14.2.Market Share Analysis By Company (2017)
     14.3. Company Profiles
            14.3.1. AbbVie, Inc. 
                      14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.1.2. Product Portfolio
                      14.3.1.3. SWOT Analysis
                      14.3.1.4. Financial Overview
                      14.3.1.5. Strategic Overview
            14.3.2. Janssen Biotech, Inc.
                      14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.2.2. Product Portfolio
                      14.3.2.3. SWOT Analysis
                      14.3.2.4. Financial Overview
                      14.3.2.5. Strategic Overview 
            14.3.3. Novartis AG 
                      14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.3.2. Product Portfolio
                      14.3.3.3. SWOT Analysis
                      14.3.3.4. Financial Overview
                      14.3.3.5. Strategic Overview
            14.3.4. Amgen, Inc. 
                      14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.4.2. Product Portfolio
                      14.3.4.3. SWOT Analysis
                      14.3.4.4. Financial Overview
                      14.3.4.5. Strategic Overview
            14.3.5. Celgene Corporation
                      14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.5.2. Product Portfolio
                      14.3.5.3. SWOT Analysis
                      14.3.5.4. Financial Overview
                      14.3.5.5. Strategic Overview
            14.3.6. Pfizer, Inc. 
                      14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.6.2. Product Portfolio
                      14.3.6.3. SWOT Analysis
                      14.3.6.4. Financial Overview
                      14.3.6.5. Strategic Overview
            14.3.7. LEO Pharma A/S 
                      14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.7.2. Product Portfolio
                      14.3.7.3. SWOT Analysis
                      14.3.7.4. Financial Overview
                      14.3.7.5. Strategic Overview
            14.3.8. Eli Lilly and Company
                      14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.8.2. Product Portfolio
                      14.3.8.3. SWOT Analysis
                      14.3.8.4. Financial Overview
                      14.3.8.5. Strategic Overview
            14.3.9. Bausch Health Companies, Inc.
                      14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.9.2. Product Portfolio
                      14.3.9.3. SWOT Analysis
                      14.3.9.4. Financial Overview
                      14.3.9.5. Strategic Overview 
            14.3.10. Sun Pharmaceuticals Ltd. 
                      14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.10.2. Product Portfolio
                      14.3.10.3. SWOT Analysis
                      14.3.10.4. Financial Overview
                      14.3.10.5. Strategic Overview
            14.3.11. Aclaris Therapeutics, Inc.
                      14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.11.2. Product Portfolio
                      14.3.11.3. SWOT Analysis
                      14.3.11.4. Financial Overview
                      14.3.11.5. Strategic Overview 
            14.3.12. Aurobindo Pharma Ltd 
                      14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.12.2. Product Portfolio
                      14.3.12.3. SWOT Analysis
                      14.3.12.4. Financial Overview
                      14.3.12.5. Strategic Overview

Table 01: Global Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 02: Global Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 03: Global Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 04: North America Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 05: North America Prescription Dermatology Therapeutics Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 06: North America Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 07: Europe Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 08: Europe Prescription Dermatology Therapeutics Value (US$ Mn) Forecast, by Product, 2016–2026
Table 09: Europe Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 10: Asia Pacific Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 11: Asia Pacific Prescription Dermatology Therapeutics Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 12: Asia Pacific Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13: Latin America Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: Latin America Prescription Dermatology Therapeutics Value (US$ Mn) Forecast, by Product Type, 2016–2026
Table 15: Latin America Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 16: Middle East & Africa Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17: Middle East & Africa Prescription Dermatology Therapeutics Value (US$ Mn) Forecast, by Product, 2016–2026
Table 18: Middle East & Africa Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

 

Figure 01: Global Prescription Dermatology Therapeutics Market Snapshot
Figure 02: Global Fluid Management Market Size (US$ Mn) and Distribution, by Region, 2017 and 2025
Figure 03: Global Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, 2016-2026
Figure 05: Global Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel (2017)
Figure 06: Global Prescription Dermatology Therapeutics Market Value Share (%), by Region (2017)
Figure 04: Global Prescription Dermatology Therapeutics Market Value Share (%), by Product Type (2017)
Figure 07: Global Prescription Dermatology Therapeutics Market Value Share Analysis, by Product Type, 2017 and 2026
Figure 08: Global Prescription Dermatology Therapeutics Market Attractiveness, by Product Type, 2018–2026
Figure 09: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Acne & Rosacea Drugs, 2016–2026
Figure 10: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Psoriasis Drugs, 2016–2026
Figure 11: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dermatitis & Seborrhea Drugs, 2016–2026
Figure 12: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Fungal Infection Drugs, 2016–2026
Figure 13: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Skin Cancer Drugs, 2016–2026
Figure 14: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
Figure 15: Global Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 17: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2016–2026
Figure 18: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Mail Order Pharmacies, 2016–2026
Figure 16: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2016–2026
Figure 19: Global Prescription Dermatology Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 20: Global Prescription Dermatology Therapeutics Market Value Share Analysis, by Region 2017 and 2026
Figure 21: Global Prescription Dermatology Therapeutics Market Attractiveness, by Region, 2018–2026
Figure 22: North America Prescription Dermatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 23: North America Prescription Dermatology Therapeutics Market Value Share (%), by Country, 2017 and 2026
Figure 24: North America Prescription Dermatology Therapeutics Market Attractiveness, by Country, 2018–2026
Figure 25: North America Prescription Dermatology Therapeutics Market Value Share (%), by Product Type, 2017 and 2026
Figure 26: North America Prescription Dermatology Therapeutics Market Attractiveness, by Product Type, 2018–2026
Figure 27: North America Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 28: North America Prescription Dermatology Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 29: Europe Prescription Dermatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 30: Europe Prescription Dermatology Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 31: Europe Prescription Dermatology Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 32: Europe Prescription Dermatology Therapeutics Market Value Share (%), by Product, 2017 and 2026
Figure 33: Europe Prescription Dermatology Therapeutics Market Attractiveness, by Product, 2018–2026
Figure 34: Europe Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 35: Europe Prescription Dermatology Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 36: Asia Pacific Prescription Dermatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 37: Asia Pacific Prescription Dermatology Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 38: Asia Pacific Prescription Dermatology Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 39: Asia Pacific Prescription Dermatology Therapeutics Market Value Share (%), by Product Type, 2017 and 2026
Figure 40: Asia Pacific Prescription Dermatology Therapeutics Market Attractiveness, by Product Type, 2018–2026
Figure 41: Asia Pacific Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 42: Asia Pacific Prescription Dermatology Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 43: Latin America Prescription Dermatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 44: Latin America Prescription Dermatology Therapeutics Market Value Share (%), by Country/Sub-region 2017 and 2026
Figure 45: Latin America Prescription Dermatology Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 46: Latin America Prescription Dermatology Therapeutics Market Value Share (%), by Product Type, 2017 and 2026
Figure 47: Latin America Prescription Dermatology Therapeutics Market Attractiveness, by Product Type, 2018–2026 
Figure 48: Latin America Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 49: Latin America Prescription Dermatology Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 50: Middle East & Africa Prescription Dermatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 51: Middle East & Africa Prescription Dermatology Therapeutics Market Value Share (%), by Country/Sub-region 2017 and 2026
Figure 52: Middle East & Africa Prescription Dermatology Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 53: Middle East & Africa Prescription Dermatology Therapeutics Market Value Share (%), by Product, 2017 and 2026
Figure 54: Middle East & Africa Prescription Dermatology Therapeutics Market Attractiveness, by Product, 2018–2026
Figure 55: Middle East & Africa Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 56: Middle East & Africa Prescription Dermatology Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 57: Global Prescription Dermatology Therapeutics Market Share Analysis, by Company (2017)
Figure 58: AbbVie, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2017
Figure 59: AbbVie, Inc. R&D Intensity and Sales & Marketing Intensity - Company Level, 2015–2016
Figure 60: AbbVie, Inc. Breakdown of Net Sales (%), by Region
Figure 61: Janssen Biotech, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2017
Figure 62: Breakdown of Net Sales (%), by Business Segment, (2017)
Figure 63: Janssen Biotech, Inc. Breakdown of Net Sales (%), by Geography (2017)
Figure 64: Janssen Biotech, Inc. R&D Intensity and Sales & Marketing Intensity - Company Level, 2016–2017
Figure 65: Janssen Biotech, Inc. Breakdown of Net Sales, by Geography (2017)
Figure 66: Janssen Biotech, Inc. Breakdown of Net Sales, by Business Segment (2017)
Figure 67: Janssen Biotech, Inc. R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2017
Figure 68: Janssen Biotech, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 69: Amgen, Inc. R&D Intensity and Sales & Marketing Intensity - Company Level, 2016–2017
Figure 70: Amgen, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2017
Figure 71: Amgen, Inc. Breakdown of Net Sales, by Region, 2017
Figure 72: Celgene Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 73: Celgene Corporation Breakdown of Net Sales (%), by Key Product (2017)
Figure 74: Celgene Corporation R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2017
Figure 75: Celgene Corporation Breakdown of Net Sales, by Geography (2017)
Figure 76; Pfizer, Inc. Breakdown of Net Sales, by Region, 2017
Figure 78: Pfizer, Inc. R&D Intensity and Sales & Marketing Intensity - Company Level, 2016–2017
Figure 79: LEO Pharma A/S Breakdown of Net Sales, by Geography (2017)
Figure 80: LEO Pharma A/S Breakdown of Net Sales, by Therapeutic Area (2017)
Figure 81: LEO Pharma A/S Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 82; Eli Lilly and Company Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 83; Eli Lilly and Company Breakdown of Net Sales (%), by Region, 2017
Figure 84 Eli Lilly and Company Research & Development Cost (US$ Mn), 2016 and 2017
Figure 85: Eli Lilly and Company Breakdown of Net Sales (%), by Business Segment, 2017
Figure 86: Bausch Health Companies, Inc. R&D Expenses (US$ Mn), 2015-2017
Figure 87: Bausch Health Companies, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 88: Bausch Health Companies, Inc. Breakdown of Net Sales (%), by Region, 2016
Figure 89: Allergan plc. R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2017
Figure 90: Allergan plc. Breakdown of Net Sales, by Business Segment (2017)
Figure 91: Allergan plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2017
Figure 92: Sun Pharmaceuticals Ltd. Breakdown of Net Sales, by Geography (2017)
Figure 93: Sun Pharmaceuticals Ltd. Breakdown of Net Sales, by Business Segment (2017)
Figure 94: Sun Pharmaceuticals Ltd. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 95: Aclaris Therapeutics, Inc. R&D Expenses (US$ Mn), 2013–2016
Figure 96: Aurobindo Pharma Ltd. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 97: Aurobindo Pharma Ltd. Breakdown of Net Sales, by Business Segment (2017)

 

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Prescription Dermatology Therapeutics Market